Drug1st-line biologic line
Mepolizumab
Anti–IL-5 monoclonal antibody
- Response rate
- Significant NPS reduction
- Onset
- 4–8 weeks
- Route
- SC 100mg every 4 weeks
- Line
- 1st-line biologic
- IgM effect
- Reduces polyp score
- Evidence level
- green
- Trial phase
- Phase 4
Evidence summary
Neutralises IL-5, reducing eosinophil maturation and survival. SYNAPSE trial demonstrated significant reduction in polyp size and need for surgery. FDA-approved 2021 for CRSwNP. May be preferred in patients with high eosinophil counts and comorbid eosinophilic asthma.
Approved indications
Conditions for which Mepolizumab has regulatory approval (not specific to rare diseases covered here):
Severe Eosinophilic AsthmaEosinophilic Granulomatosis with PolyangiitisChronic Rhinosinusitis with Nasal PolypsHypereosinophilic Syndrome
Drug identifiers
| DrugBank | DB11603 ↗ |
| ATC Code | R03DX09 |
| Open Targets | CHEMBL1201832 ↗ |
Molecular targets
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| IL-5 | Eosinophil survival factor | Elevated | established |
| Eosinophils | Effector granulocytes | Massively infiltrated in tissue | established |